NLS SwedenBIO

As always, J.P. Morgan (JPM) kicks off the year as the key event for life science executives to exchange insights and predict the direction of the industry.

The life science innovation gap between the EU and its global competitors continues to widen while the number of EU regulations affecting the industry is rising. Are we heading in the right direction?

Company creation, metabolic diseases, and AI-powered drug discovery are amongst the hottest trends in 2024. Life science executives have gathered to discuss current matters in the industry several times during this spring, starting with J.P. Morgan’s Annual Healthcare week and followed by Bio-Europe Spring. SwedenBIO was there to connect Swedish life sciences with our international […]

Over the past ten years, the life science industry across the Nordics has shown tremendous growth. Despite some hiccups along the way caused by global upheavals, the region’s industry continues to trend upwards. Today, the five Nordic countries together boast around 700-800 life science companies, with biotech and then medtech being the most prominent areas, […]

The newly proposed EU pharmaceutical legislation aims to increase access to medicines for patients in all EU member states, but as the proposed changes in intellectual property rights for new drugs put European innovation at risk it may have the opposite effect. The European Commission put forth its long-awaited proposal for the new European pharmaceutical […]

Sweden’s plethora of micro-sized and small biotech companies create a richness of innovations and a culture of knowledge sharing. To bring good science to market, they also need business intelligence and the right capital. Sweden boasts a thriving growth of micro-sized and small biotech companies that contribute to a dynamic, innovative climate and a culture […]